Adam Evertts
Long only, value

Flexion Therapeutics Is On A Potentially Accelerated Path For Osteoarthritis Drug

Flexion Therapeutics (NASDAQ:FLXN) is part of the seemingly never-ending wave of biotechnology companies going public this year, and raised $67 million in its February debut. The company focuses on drugs for pain, and its lead candidate FX006 is a sustained-release version of the routinely used steroid triamcinolone acetonide (TCA) for the treatment of pain associated with moderate to severe osteoarthritis (NYSE:OA) of the knee. Flexion will seek a 505(b)(2) pathway for the development of FX006, which comes with several advantages to the company and investors alike. This potentially accelerated development, some encouraging initial data, and the cash to fund new trials suggest that Flexion could rally in 2014.

505(b)(2) Pathway is the Key

The FDA...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details